These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 16417259)

  • 1. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.
    Doronina SO; Mendelsohn BA; Bovee TD; Cerveny CG; Alley SC; Meyer DL; Oflazoglu E; Toki BE; Sanderson RJ; Zabinski RF; Wahl AF; Senter PD
    Bioconjug Chem; 2006; 17(1):114-24. PubMed ID: 16417259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
    Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of potent monoclonal antibody auristatin conjugates for cancer therapy.
    Doronina SO; Toki BE; Torgov MY; Mendelsohn BA; Cerveny CG; Chace DF; DeBlanc RL; Gearing RP; Bovee TD; Siegall CB; Francisco JA; Wahl AF; Meyer DL; Senter PD
    Nat Biotechnol; 2003 Jul; 21(7):778-84. PubMed ID: 12778055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel peptide linkers for highly potent antibody-auristatin conjugate.
    Doronina SO; Bovee TD; Meyer DW; Miyamoto JB; Anderson ME; Morris-Tilden CA; Senter PD
    Bioconjug Chem; 2008 Oct; 19(10):1960-3. PubMed ID: 18803412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate.
    Hamblett KJ; Senter PD; Chace DF; Sun MM; Lenox J; Cerveny CG; Kissler KM; Bernhardt SX; Kopcha AK; Zabinski RF; Meyer DL; Francisco JA
    Clin Cancer Res; 2004 Oct; 10(20):7063-70. PubMed ID: 15501986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of linker stability to the activities of anticancer immunoconjugates.
    Alley SC; Benjamin DR; Jeffrey SC; Okeley NM; Meyer DL; Sanderson RJ; Senter PD
    Bioconjug Chem; 2008 Mar; 19(3):759-65. PubMed ID: 18314937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates.
    Jeffrey SC; Andreyka JB; Bernhardt SX; Kissler KM; Kline T; Lenox JS; Moser RF; Nguyen MT; Okeley NM; Stone IJ; Zhang X; Senter PD
    Bioconjug Chem; 2006; 17(3):831-40. PubMed ID: 16704224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.
    Francisco JA; Cerveny CG; Meyer DL; Mixan BJ; Klussman K; Chace DF; Rejniak SX; Gordon KA; DeBlanc R; Toki BE; Law CL; Doronina SO; Siegall CB; Senter PD; Wahl AF
    Blood; 2003 Aug; 102(4):1458-65. PubMed ID: 12714494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel immunoconjugates comprised of streptonigrin and 17-amino-geldanamycin attached via a dipeptide-p-aminobenzyl-amine linker system.
    Burke PJ; Toki BE; Meyer DW; Miyamoto JB; Kissler KM; Anderson M; Senter PD; Jeffrey SC
    Bioorg Med Chem Lett; 2009 May; 19(10):2650-3. PubMed ID: 19386499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.
    Tse KF; Jeffers M; Pollack VA; McCabe DA; Shadish ML; Khramtsov NV; Hackett CS; Shenoy SG; Kuang B; Boldog FL; MacDougall JR; Rastelli L; Herrmann J; Gallo M; Gazit-Bornstein G; Senter PD; Meyer DL; Lichenstein HS; LaRochelle WJ
    Clin Cancer Res; 2006 Feb; 12(4):1373-82. PubMed ID: 16489096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment.
    McDonagh CF; Turcott E; Westendorf L; Webster JB; Alley SC; Kim K; Andreyka J; Stone I; Hamblett KJ; Francisco JA; Carter P
    Protein Eng Des Sel; 2006 Jul; 19(7):299-307. PubMed ID: 16644914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minor groove binder antibody conjugates employing a water soluble beta-glucuronide linker.
    Jeffrey SC; Nguyen MT; Moser RF; Meyer DL; Miyamoto JB; Senter PD
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2278-80. PubMed ID: 17293111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugates.
    Jeffrey SC; Torgov MY; Andreyka JB; Boddington L; Cerveny CG; Denny WA; Gordon KA; Gustin D; Haugen J; Kline T; Nguyen MT; Senter PD
    J Med Chem; 2005 Mar; 48(5):1344-58. PubMed ID: 15743178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.
    Law CL; Cerveny CG; Gordon KA; Klussman K; Mixan BJ; Chace DF; Meyer DL; Doronina SO; Siegall CB; Francisco JA; Senter PD; Wahl AF
    Clin Cancer Res; 2004 Dec; 10(23):7842-51. PubMed ID: 15585616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological evaluation of antibody-drug conjugates comprised of potent camptothecin analogues.
    Burke PJ; Senter PD; Meyer DW; Miyamoto JB; Anderson M; Toki BE; Manikumar G; Wani MC; Kroll DJ; Jeffrey SC
    Bioconjug Chem; 2009 Jun; 20(6):1242-50. PubMed ID: 19469529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index.
    McDonagh CF; Kim KM; Turcott E; Brown LL; Westendorf L; Feist T; Sussman D; Stone I; Anderson M; Miyamoto J; Lyon R; Alley SC; Gerber HP; Carter PJ
    Mol Cancer Ther; 2008 Sep; 7(9):2913-23. PubMed ID: 18790772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker.
    Shi B; Wu M; Li Z; Xie Z; Wei X; Fan J; Xu Y; Ding D; Akash SH; Chen S; Cao S
    Cancer Med; 2019 Apr; 8(4):1793-1805. PubMed ID: 30843650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance.
    Hamann PR; Hinman LM; Beyer CF; Greenberger LM; Lin C; Lindh D; Menendez AT; Wallace R; Durr FE; Upeslacis J
    Bioconjug Chem; 2005; 16(2):346-53. PubMed ID: 15769088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates.
    Sutherland MS; Sanderson RJ; Gordon KA; Andreyka J; Cerveny CG; Yu C; Lewis TS; Meyer DL; Zabinski RF; Doronina SO; Senter PD; Law CL; Wahl AF
    J Biol Chem; 2006 Apr; 281(15):10540-7. PubMed ID: 16484228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.